Wealthcare Advisory Partners LLC Trims Holdings in Johnson & Johnson (NYSE:JNJ)

Wealthcare Advisory Partners LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,350 shares of the company's stock after selling 4,315 shares during the quarter. Wealthcare Advisory Partners LLC's holdings in Johnson & Johnson were worth $10,463,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. IFS Advisors LLC lifted its stake in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth about $31,000. RPg Family Wealth Advisory LLC purchased a new stake in Johnson & Johnson during the 3rd quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after purchasing an additional 91 shares during the last quarter. Finally, Activest Wealth Management acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $40,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently issued reports on JNJ shares. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They set an "outperform" rating and a $190.00 target price on the stock. Guggenheim boosted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Finally, StockNews.com cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $174.29.

Johnson & Johnson Price Performance

NYSE:JNJ traded down $0.74 during trading hours on Friday, reaching $147.03. 10,678,393 shares of the company were exchanged, compared to its average volume of 6,880,262. The stock's 50-day moving average is $148.51 and its 200-day moving average is $156.03. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The firm has a market cap of $353.99 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is presently 71.78%.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.